AUTHOR CORRECTION
Volume 65, no. 2, e02290-20, 2021, https://doi.org/10.1128/AAC.02290-20. In the penultimate paragraph of the Discussion section in this paper, the authors stated that one limitation of this study was that all patients received remdesivir lyophilized powder, which contains half the amount of sulfobutylether-beta-cyclodextrin sodium (SBECD) as the injectable solution. Upon further review, it was found that patients exclusively received remdesivir injectable solution in lieu of the lyophilized powder. While the authors take full responsibility for this correction, the interpretation and conclusions of the manuscript remain the same.